Aliases & Classifications for Morbid Obesity

Aliases & Descriptions for Morbid Obesity:

Name: Morbid Obesity 38 12 29 14
Obesity, Morbid 42 69
Severe Obesity 12 14
Obesity Morbid 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11981
ICD9CM 35 278.01
MeSH 42 D009767
NCIt 47 C34858
UMLS 69 C0028756

Summaries for Morbid Obesity

MalaCards based summary : Morbid Obesity, also known as obesity, morbid, is related to lipomatosis and myocardial infarction, and has symptoms including overweight and obesity, metabolically benign. An important gene associated with Morbid Obesity is LEP (Leptin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Heparin and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, skeletal muscle and kidney, and related phenotypes are adipose tissue and behavior/neurological

Related Diseases for Morbid Obesity

Diseases related to Morbid Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
id Related Disease Score Top Affiliating Genes
1 lipomatosis 29.1 ADIPOQ CRP INS LEP LPL
2 myocardial infarction 29.0 ADIPOQ ALB CRP INS RETN
3 morbid obesity and spermatogenic failure 12.3
4 obesity, morbid, due to leptin receptor deficiency 11.2
5 obesity, morbid, due to leptin deficiency 11.2
6 obesity 10.9
7 obesity, pparg-related 10.3 ADRB3 MC4R
8 acute infection of pinna 10.3 CRP INS
9 obesity, ucp3-related 10.3 GHRL MC4R
10 microphthalmia, syndromic 8 10.3 GCG INS
11 leg dermatosis 10.2 ADIPOQ INS LEP
12 acrocephalopolydactyly 10.2 ADIPOQ LEP RETN
13 malignant perineurioma 10.2 ADIPOQ LEP RETN
14 mucinoses 10.2 ADIPOQ LEP RETN
15 cortical blindness mental retardation polydactyly 10.2 ADIPOQ LEP RETN
16 autoimmune disease 1 10.2 CRP GCG INS
17 glomangiomyoma 10.2 GHRL INS LEP
18 posterior uveal melanoma 10.2 ADIPOQ CRP INS
19 cataract 10.2 ALB CRP INS
20 not otherwise specified 3-mga-uria type 10.2 ADIPOQ INS LEP RETN
21 meningitis 10.2 ADIPOQ INS LEP LEPR
22 thymus clear cell carcinoma 10.2 ADIPOQ INS LEP RETN
23 neurogenic arthropathy 10.1 ADIPOQ GCG INS LEP
24 exostosis 10.1 GHRL INS LEP
25 gait apraxia 10.1 ADIPOQ ALB CRP
26 shoulder impingement syndrome 10.1 ALB CRP
27 breast hemangiopericytoma 10.1 CRP HCRT LEP
28 polycythemia due to hypoxia 10.1 CCK CRP
29 familial nephrotic syndrome 10.1 ALB CRP LEP
30 peripheral degeneration of cornea 10.1 GCG INS PYY
31 antidepressant type abuse 10.1 ADIPOQ ADRB3 INS LEP RETN
32 chronic myocardial ischemia 10.1 ALB CRP INS LEP
33 exophthalmic ophthalmoplegia 10.1 ADIPOQ ALB LEP LEPR
34 chronic tic disorder 10.1 ADIPOQ ALB LEP LEPR
35 central nervous system leiomyoma 10.1 ALB CRP GHRL LEP
36 fissured tongue 10.1 ALB CCK INS
37 hyperlipoproteinemia type iv 10.0 ADIPOQ ALB CRP INS LEP
38 prader-willi syndrome 10.0
39 duodenitis 10.0
40 joint disorders 10.0 CRP INS LPL
41 uterine ligament clear cell adenocarcinoma 10.0 ALB CRP GCG GHRL
42 rickets 10.0 CCK GCG PYY
43 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.0 CCK GHRL PYY
44 chondroma 10.0 CCK CRP GCG INS LEP
45 lymphoid leukemia 10.0 ADIPOQ ALB INS LEP LEPR
46 submucous uterine fibroid 10.0 ALB INS
47 esophagitis 10.0
48 gastroesophageal reflux 10.0
49 calcinosis 10.0 ALB CRP INS
50 brain stem glioma 10.0 ADIPOQ ALB GCG INS LEP

Graphical network of the top 20 diseases related to Morbid Obesity:



Diseases related to Morbid Obesity

Symptoms & Phenotypes for Morbid Obesity

UMLS symptoms related to Morbid Obesity:


overweight, obesity, metabolically benign

MGI Mouse Phenotypes related to Morbid Obesity:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.28 ADIPOQ ADRB3 CEP19 FABP2 FTO GHRL
2 behavior/neurological MP:0005386 10.22 ADIPOQ ADRB3 CCK CEP19 FTO GHRL
3 homeostasis/metabolism MP:0005376 10.21 LEPR LPL MC3R MC4R PYY RETN
4 growth/size/body region MP:0005378 10.13 ADIPOQ FABP2 FTO HCRT INS LEP
5 endocrine/exocrine gland MP:0005379 10.02 ADIPOQ ADRB3 ALB CCK FTO GHRL
6 liver/biliary system MP:0005370 9.85 ADIPOQ ALB FABP2 FTO INS LEP
7 muscle MP:0005369 9.5 HCRT INS LEP LEPR LPL ADIPOQ
8 renal/urinary system MP:0005367 9.17 ADIPOQ ALB FABP2 FTO INS LEP

Drugs & Therapeutics for Morbid Obesity

Drugs for Morbid Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 371)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2 9005-49-6 772 46507594
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
4
Acetaminophen Approved Phase 4,Phase 3,Phase 1 103-90-2 1983
5
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
6
Rocuronium Approved Phase 4,Phase 2 119302-91-9, 143558-00-3 441290
7
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
8
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
10
Liraglutide Approved Phase 4 204656-20-2
11 Nadroparin Approved Phase 4 9041-08-1
12
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
13
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 5460373 44475014
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
15
Dalteparin Approved Phase 4,Phase 1 9041-08-1
16
chenodeoxycholic acid Approved Phase 4,Phase 2,Phase 1 474-25-9 10133
17
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
18
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
19
Ibuprofen Approved Phase 4 15687-27-1 3672
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
22
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
23
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
24
Cefazolin Approved Phase 4 25953-19-9 656510 33255
25
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
26
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
27
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
28
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
29
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
30
Coal tar Approved Phase 4 8007-45-2
31
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
32
Verapamil Approved Phase 4 52-53-9 2520
33
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
34
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
36 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
38
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
39
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 1 67-97-0 6221 10883523 5280795
40
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
41
Methylene blue Investigational Phase 4,Phase 1,Phase 2 61-73-4
42 calcium heparin Phase 4
43 Atorvastatin Calcium Phase 4 134523-03-8
44 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
45 calcium channel blockers Phase 4,Early Phase 1
46 Adjuvants, Anesthesia Phase 4,Phase 3
47 Adrenergic Agents Phase 4,Phase 3,Phase 1,Early Phase 1
48 Narcotics Phase 4,Phase 2,Phase 3
49 GABA Agents Phase 4
50 GABA Modulators Phase 4

Interventional clinical trials:

(show top 50) (show all 585)
id Name Status NCT ID Phase
1 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
2 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4
3 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 VAS Correlation With BMI Unknown status NCT02017314 Phase 4
6 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
7 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
8 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4
9 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4
10 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
11 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4
12 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4
13 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
14 Pharmacokinetics of Propofol in Morbidly Obese Patients Completed NCT01536002 Phase 4
15 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
16 Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery Completed NCT02778958 Phase 4
17 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
18 Garcinia Mangostana Extracts in the Management of Weight Loss Completed NCT02823561 Phase 4
19 Population PK/PD of Propofol in the Morbidly Obese Patient Completed NCT00395681 Phase 4
20 Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Completed NCT02340247 Phase 4
21 Increased Cefazolin During Cesarean Delivery in Obese Population Completed NCT02049944 Phase 4
22 Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery Completed NCT01064596 Phase 4
23 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Completed NCT00608712 Phase 4
24 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4
25 A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery Completed NCT02233400 Phase 4
26 The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron Completed NCT02390921 Phase 4
27 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4
28 Intravenous Ibuprofen for Laparoscopic Bariatric Surgery Completed NCT01707251 Phase 4
29 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Recruiting NCT01913392 Phase 4
30 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4
31 Micafungin Pharmacokinetics in Obese Patients Recruiting NCT03102658 Phase 4
32 Preoperative Condition in Giant Obese Patients Recruiting NCT02616003 Phase 4
33 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02952963 Phase 4
34 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4
35 Treatment of Periodontitis in Obese Individuals Recruiting NCT03103204 Phase 4
36 Aspiration Therapy in Asian Patients Recruiting NCT02881684 Phase 4
37 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Recruiting NCT02118844 Phase 4
38 Ketamine for Pain Relief in Bariatric Surgery Recruiting NCT03052673 Phase 4
39 Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function and Lung Regional Ventilation on Bariatric Surgery Recruiting NCT02577744 Phase 4
40 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Recruiting NCT02167620 Phase 4
41 Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes Recruiting NCT02746874 Phase 4
42 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Active, not recruiting NCT02206256 Phase 4
43 Surgical Conditions During Laparoscopic Bariatric Surgery Active, not recruiting NCT02703909 Phase 4
44 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Active, not recruiting NCT02374632 Phase 4
45 Efficacy of Vitamin D Supplementation in Obese Children Enrolling by invitation NCT02956408 Phase 4
46 Treatment of Hypoglycemia Following Gastric Bypass Surgery Enrolling by invitation NCT02527993 Phase 4
47 Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) Not yet recruiting NCT02320604 Phase 4
48 DPE Technique in Labor Epidural for Morbidly Obese Women Not yet recruiting NCT03074695 Phase 4
49 Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery Withdrawn NCT00361985 Phase 4
50 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4

Search NIH Clinical Center for Morbid Obesity

Cochrane evidence based reviews: obesity, morbid

Genetic Tests for Morbid Obesity

Genetic tests related to Morbid Obesity:

id Genetic test Affiliating Genes
1 Morbid Obesity 29

Anatomical Context for Morbid Obesity

MalaCards organs/tissues related to Morbid Obesity:

39
Liver, Skeletal Muscle, Kidney, Thyroid, Testes, Bone, Heart

Publications for Morbid Obesity

Articles related to Morbid Obesity:

(show top 50) (show all 755)
id Title Authors Year
1
Zinc Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27885534 )
2017
2
Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy for morbid obesity. ( 28069786 )
2017
3
Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. ( 28077498 )
2017
4
The effect of morbid obesity on morphine glucuronidation. ( 27609660 )
2016
5
Early endometrial carcinoma therapy in morbid obesity: A retrospective study comparing open and laparoscopic. ( 27102329 )
2016
6
Relationship Between Vitamin D Deficiency and the Components of Metabolic Syndrome in Patients with Morbid Obesity, Before and 1A Year After Laparoscopic Roux-en-Y Gastric Bypass or Sleeve Gastrectomy. ( 27864670 )
2016
7
Evaluation of laparoscopic sleeve gastrectomy compared with laparoscopic Roux-en-Y gastric bypass for people with morbid obesity: A systematic review and meta-analysis. ( 27453881 )
2016
8
The Correlation Of Increased Crp Levels With NFKB1 And TLR2 Polymorphisms In Case Of Morbid Obesity. ( 27507606 )
2016
9
Thrombophilia after total gastrectomy for morbid obesity. ( 26911993 )
2016
10
Psychopathological behaviour and cognition in morbid obesity. ( 28029083 )
2016
11
Leptin receptor gene polymorphisms and morbid obesity in Mexican patients. ( 28096764 )
2016
12
A case report of chylous ascites after gastric bypass for morbid obesity. ( 27846453 )
2016
13
A Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity. ( 27049488 )
2016
14
Morbid Obesity in Total Hip Arthroplasty: Redefining Outcomes for Operative Time, Length of Stay, and Readmission. ( 26994650 )
2016
15
Gastrointestinal symptoms and food intolerance 2 years after laparoscopic Roux-en-Y gastric bypass for morbid obesity. ( 27990637 )
2016
16
Morbid obesity increases risk of morbidity and reoperation in resection of benign cranial nerve neoplasms. ( 27434528 )
2016
17
The impact of morbid obesity on resource utilization after renal transplantation. ( 27574775 )
2016
18
Simultaneous occurrence of metabolic, hematologic, neurologic and cardiac complications after Roux-en-Y gastric bypass for morbid obesity. ( 27491655 )
2016
19
Gastric bezoar after Roux-en-Y gastric bypass for morbid obesity: A case report. ( 27107501 )
2016
20
The association between severity of King's Obesity Staging Criteria scores and treatment choice in patients with morbid obesity: a retrospective cohort study. ( 27980795 )
2016
21
Modulation of Irisin and Physical Activity on Executive Functions in Obesity and Morbid obesity. ( 27476477 )
2016
22
Nursing care in the use of ERAS programme in patients with morbid obesity. ( 28531744 )
2016
23
The Association of Sleep Duration and Morbid Obesity in a Working Population: The Baptist Health South Florida Employee Study. ( 28026999 )
2016
24
Update on Treatment ofA Morbid Obesity withA Adjustable Gastric Banding. ( 27473802 )
2016
25
Morbid Obesity and Lumbar Fusion in Patients over 65 Years of Age: Complications, Readmissions, Costs, and Length of Stay. ( 27196019 )
2016
26
The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. ( 27893763 )
2016
27
Chronic Abdominal Pain and Symptoms 5A Years After Gastric Bypass for Morbid Obesity. ( 28028658 )
2016
28
Erratum to: Preoperative Predictive Factors of Successful Weight Loss and Glycaemic Control 1 Year After Gastric Bypass for Morbid Obesity. ( 26932812 )
2016
29
Laparoscopic sleeve gastrectomy as first-line surgical treatment for morbid obesity among adolescents. ( 27637140 )
2016
30
Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. ( 27072554 )
2016
31
Sleeve Gastrectomy Combined with the Simplified Hill Repair in the Treatment of Morbid Obesity and Gastro-esophageal Reflux Disease: Preliminary Results in 14 Patients. ( 27896401 )
2016
32
Consequences of morbid obesity on the kidney. Where are we going? ( 27994854 )
2016
33
Evaluating the Obstetrical Implications of Antenatal Testing for Women with Morbid Obesity: Maternal and Fetal Outcomes of Increased Surveillance. ( 26960703 )
2016
34
Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed? ( 27092024 )
2016
35
Novel Endoscopic and Surgical Techniques for Treatment of Morbid Obesity: A Glimpse into the Future. ( 27473806 )
2016
36
Patient Selection and Surgical Management of High-Risk Patients with Morbid Obesity. ( 27473799 )
2016
37
Erratum to: Relationship Between Vitamin D Deficiency and the Components of Metabolic Syndrome in Patients with Morbid Obesity, Before and 1A Year After Laparoscopic Roux-en-Y Gastric Bypass or Sleeve Gastrectomy. ( 28035524 )
2016
38
Decomposing trends in adult body mass index, obesity, and morbid obesity, 1971-2012. ( 27597540 )
2016
39
SY 06-3 ROLE OF SURGICAL TREATMENT OF MORBID OBESITY. ( 27642934 )
2016
40
Morbid obesity and outcome of ectopic pregnancy following capped single-dose regimen methotrexate. ( 27844211 )
2016
41
Predictors of Inadequate Weight Loss After Laparoscopic Gastric Bypass for Morbid Obesity. ( 27943095 )
2016
42
Copper Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27034062 )
2016
43
Long-Term Results of Laparoscopic Sleeve Gastrectomy for Morbid Obesity: 5 to 8-Year Results. ( 27178407 )
2016
44
Laparoscopic sleeve gastrectomy with duodeno-jejunal bypass for morbid obesity in a patient with situs inversus totalis. ( 27140835 )
2016
45
Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. ( 27861111 )
2016
46
Trajectories of physical and mental health among persons with morbid obesity and persons with COPD: a longitudinal comparative study. ( 27175082 )
2016
47
Relative prosthesis-patient mismatch after transcatheter aortic valve replacement: The impact of morbid obesity. ( 27566959 )
2016
48
The retinal nerve fiber layer, choroidal thickness, and central macular thickness in morbid obesity: an evaluation using spectral-domain optical coherence tomography. ( 27010146 )
2016
49
The Socioeconomic Impact of Morbid Obesity and Factors Affecting Access to Obesity Surgery. ( 27473794 )
2016
50
Laparoscopic stomach intestinal pylorus sparing surgery in a patient with morbid obesity and situs inversus: first video case report. ( 27865811 )
2016

Variations for Morbid Obesity

ClinVar genetic disease variations for Morbid Obesity:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh37 Chromosome 3, 12422848: 12422848

Expression for Morbid Obesity

LifeMap Discovery
Genes differentially expressed in tissues of Morbid Obesity patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Skeletal Muscle - 5.09 0.006
2 SLN sarcolipin Skeletal Muscle - 4.64 0.007
Search GEO for disease gene expression data for Morbid Obesity.

Pathways for Morbid Obesity

Pathways related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 ADRB3 CCK GCG GHRL HCRT INS
2
Show member pathways
12.92 ADRB3 CCK GCG GHRL HCRT LEP
3 12.28 ADIPOQ FTO GCG INS
4
Show member pathways
12.21 ADIPOQ INS LEP LEPR
6
Show member pathways
11.97 GCG GHRL INS LEP
7 11.79 ADRB3 GCG MC3R MC4R
8 11.51 ADIPOQ FABP2 LPL
9 11.47 ADIPOQ LEP LEPR
10 11.44 ADIPOQ INS LEP LPL
11 11.24 INS LEP LEPR
12 11.14 ADIPOQ INS LEP LPL RETN
13
Show member pathways
10.91 CRP LEP LEPR

GO Terms for Morbid Obesity

Cellular components related to Morbid Obesity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ADIPOQ ALB CCK CRP GCG GHRL
2 endoplasmic reticulum lumen GO:0005788 9.46 ALB GCG GHRL INS
3 extracellular region GO:0005576 9.44 ADIPOQ ALB CCK CRP GCG GHRL
4 secretory granule lumen GO:0034774 9.43 GCG GHRL INS

Biological processes related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 ADIPOQ CCK INS
2 positive regulation of MAPK cascade GO:0043410 9.8 ADRB3 INS LEP
3 glucose homeostasis GO:0042593 9.78 ADIPOQ INS LEP LEPR
4 response to insulin GO:0032868 9.76 LEP MC4R RETN
5 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.71 ADRB3 MC3R MC4R
6 glucose metabolic process GO:0006006 9.71 ADIPOQ GHRL INS LEP
7 positive regulation of cAMP biosynthetic process GO:0030819 9.67 GCG MC3R MC4R
8 positive regulation of cellular protein metabolic process GO:0032270 9.64 ADIPOQ INS
9 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.64 ADIPOQ CRP
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.63 INS LEP
11 sexual reproduction GO:0019953 9.62 LEP LEPR
12 adult feeding behavior GO:0008343 9.61 GHRL LEP
13 negative regulation of lipid storage GO:0010888 9.61 CRP LEP
14 temperature homeostasis GO:0001659 9.61 ADRB3 FTO HCRT
15 leptin-mediated signaling pathway GO:0033210 9.6 LEP LEPR
16 diet induced thermogenesis GO:0002024 9.59 ADRB3 MC4R
17 negative regulation of appetite GO:0032099 9.58 CCK LEP
18 negative regulation of vasodilation GO:0045908 9.57 CRP INS
19 regulation of bone remodeling GO:0046850 9.56 LEP LEPR
20 feeding behavior GO:0007631 9.56 GCG HCRT MC4R PYY
21 negative regulation of gluconeogenesis GO:0045721 9.54 ADIPOQ INS LEPR
22 regulation of brown fat cell differentiation GO:0090335 9.52 FTO LEP
23 regulation of metabolic process GO:0019222 9.51 LEP MC4R
24 regulation of feeding behavior GO:0060259 9.5 LEPR MC3R MC4R
25 bone growth GO:0098868 9.46 LEP LEPR
26 negative regulation of feeding behavior GO:2000252 9.33 INS MC4R RETN
27 energy reserve metabolic process GO:0006112 9.26 ADRB3 LEP LEPR MC4R
28 eating behavior GO:0042755 9.02 ADRB3 CCK HCRT LEP PYY
29 G-protein coupled receptor signaling pathway GO:0007186 10.09 ADRB3 GCG GHRL INS MC3R MC4R

Molecular functions related to Morbid Obesity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.37 ALB FABP2
2 neuropeptide binding GO:0042923 9.32 MC3R MC4R
3 melanocortin receptor activity GO:0004977 9.26 MC3R MC4R
4 hormone activity GO:0005179 9.23 ADIPOQ CCK GCG GHRL INS LEP
5 melanocyte-stimulating hormone receptor activity GO:0004980 9.16 MC3R MC4R
6 neuropeptide hormone activity GO:0005184 9.13 CCK HCRT PYY

Sources for Morbid Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....